查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2120925

2034年注射用生物材料市場預測－全球分析（依材料種類、製劑類型、生物材料功能、交聯機制、給藥途徑、分解特性、治療應用、最終使用者及地區分類）

Injectable Biomaterials Market Forecasts To 2034 - Global Analysis By Material Type, Formulation Type, Biomaterial Function, Crosslinking Mechanism, Administration Route, Degradation Profile, Therapeutic Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

據 Stratistics MRC 稱，到 2026 年，全球注射用生物材料市場規模將達到 133 億美元，預計在預測期內將以 9.7% 的複合年成長率成長，到 2034 年將達到 278 億美元。

注射型生物材料市場專注於用於組織再生、藥物傳輸、傷口修復和微創醫療手術的注射型生物材料製劑。主要材料包括注射型水凝膠、膠原蛋白和細胞外基質產品、合成聚合物、複合材料、可黏附於受損組織部位的支架系統。市場成長的促進因素包括：對微創手術需求的不斷成長、整形外科和組織相關疾病的增加、再生醫學的進步以及生物材料在藥物和細胞傳遞中的廣泛應用。生物分解性、生物相容性和刺激響應性材料的進步正在提高治療效果。北美、歐洲和亞太地區憑藉其先進的醫療保健體系、研發投入、技術發展和不斷擴展的臨床應用，仍然是重要的市場。

整形外科和肌肉骨骼疾病的盛行率增加

全球整形外科和肌肉骨骼疾病負擔日益加重，顯著推動了對注射型生物材料技術的需求。針對骨關節炎、軟骨劣化、骨損傷、肌腱損傷和椎間盤退化等疾病，亟需有效的組織修復方法。注射型生物材料可望以微創方式到達損傷部位，同時提供機械支撐、局部治療或促進組織再生的環境。人口老化、肥胖率上升、體能活動增加、運動傷害以及預期壽命延長等因素，都導致需要接受肌肉骨骼治療的患者數量不斷增加。這些趨勢推動了注射型水凝膠、膠原蛋白基質、骨骼替代物以及用於再生醫學的生物材料製劑的持續研發和臨床研究。

高昂的研發和製造成本

注射用生物材料的研發和生產會帶來巨大的經濟負擔，這可能會限制市場擴張。企業在產品上市前，必須在材料研究、配方最佳化、生物相容性測試、臨床前評估、臨床試驗和法規遵循等方面投入大量資金。此外，生產還需要專門的設施、無菌生產環境、先進的加工技術和嚴格的品管體系，所有這些都會推高整體成本。對於資金籌措有限的新創公司和中小型生技公司而言，這些要求可能構成重大障礙。因此，巨額投資的需求會導致研發週期延長、商業性可行專案數量減少，並使新興企業更難與擁有完善基礎設施和雄厚財力的大型企業競爭。

開發智慧、刺激響應型生物材料

用於注射的智慧刺激響應型生物材料能夠響應特定的生物或環境條件，從而開闢了市場拓展的新途徑。這些系統可以回應溫度、酸度、酵素、光和其他生理訊號，實現可控的結構變化和治療物質的釋放。這些特性有望實現更精準的藥物和生長因子遞送，同時最大限度地減少對周圍健康組織的損傷。隨著對熱響應型、酵素敏感型、自癒合型和光交聯型注射製劑的研究不斷深入，其應用範圍也不斷擴大。隨著這些先進技術走向臨床應用，它們有望使新產品脫穎而出，提高治療的精準度，並在再生醫學和局部給藥領域開闢更多機會。

供應鏈中斷及原料供應情況

由於注射用生物材料生產商依賴特殊原料，因此極易受到供應鏈中斷的影響。生產過程可能需要高品質的膠原蛋白、明膠、透明質酸、聚合物、胜肽、蛋白質、交聯劑以及其他嚴格控制的成分。供不應求、運輸問題、地緣政治事件、供應商集中度以及原料價格波動都可能導致生產成本上升和生產中斷。生物來源成分面臨更多挑戰，它們需要可追溯性、嚴格的品質標準和可靠的供應商，因此難以快速找到替代方案。長期中斷可能導致產品供應延遲、價格上漲，並影響醫療保健供應的連續性。因此，生產商可能需要確保擁有多家認證供應商，制定更完善的庫存計劃，並實施更具彈性的籌資策略，以應對這些潛在威脅。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為注射用生物材料市場帶來了巨大的短期挑戰，主要體現在部分治療的延遲、再生醫學研究的中斷、臨床試驗的延誤以及整個醫療供應鏈的中斷。醫療機構將資源轉向應對疫情，限制了涉及整形外科修復、組織再生和其他注射用生物材料的手術。此外，實驗室限制和臨床環境的減少也影響了研發活動。另一方面，疫情加速了用於再生醫學、組織損傷和免疫相關應用的生物材料的研究。隨著常規醫療服務的恢復，推遲的手術和恢復的研究活動為市場復甦奠定了基礎。

在預測期內，「天然生物材料」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，天然生物材料將佔據最大的市場佔有率，這主要得益於其優異的生物學特性和在注射療法中的廣泛應用。膠原蛋白、透明質酸、明膠、藻酸鹽、幾丁聚醣、纖維蛋白和絲素蛋白因其與生物環境的良好相容性以及促進細胞間相互作用和組織再生的能力而備受重視。這些材料可被添加到注射用水凝膠和其他製劑中，用於組織修復、藥物傳遞和再生醫學。它們能夠模擬天然細胞外環境的特性，這使得這些材料在醫療應用方面特別引人注目。持續的研發和製劑改進正在進一步鞏固這些材料在先進注射用生物材料開發中的作用。

在預測期內，「神經系統應用」細分市場預計將呈現最高的複合年成長率。

在預測期內，受人們對用於神經系統再生和修復的可注射生物材料日益成長的興趣推動，神經系統應用領域預計將呈現最高的成長率。可注射水凝膠尤其具有前景，因為它們可以透過微創手術給藥，並能創造類似天然神經組織的支撐環境。這些系統能夠將治療藥物、細胞和生長因子局部遞送至大腦、脊髓和周邊神經等難以觸及的區域。它們的生物分解性、柔軟性和在體內凝膠化的能力進一步增強了其應用潛力。對神經組織工程和先進可注射水凝膠平台的持續研究有望擴大這些技術在神經再生療法中的應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健體系、廣泛的生物醫學研究以及再生醫學的日益普及。對生物材料開發、組織工程、生物技術和微創醫學的大力投資，正在創造有利的市場環境。該地區還擁有完善的科技公司、學術機構、臨床中心和研究機構生態系統，為注射材料的創新提供支援。注射材料在整形外科修復、傷口管理、組織再生和藥物傳輸等領域的應用不斷擴展，正在推動該地區的需求成長。此外，持續的臨床研究、技術進步和商業化措施預計將進一步鞏固北美在注射生物材料產業的地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的改善、再生醫學投資的增加以及微創療法的日益普及。全部區域不斷成長的醫療需求正在增加整形外科、組織修復和再生醫學領域的應用機會。中國、日本、韓國和印度等國家正在加強其在生物材料領域的研發和生物技術能力，從而推動技術進步。不斷成長的醫療支出和先進醫療技術的普及也進一步促進了市場發展。全部區域生物材料和再生醫學領域的強勁成長為擴大注射型生物材料的應用範圍並加速其在全部區域的普及應用奠定了良好的基礎。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球注射用生物材料市場：依材料類型分類

  • 天然生物材料
  • 合成生物材料
  • 半合成生物材料
  • 複合生物材料

第6章 全球注射用生物材料市場：依製劑類型分類

  • 注射用水凝膠
  • 注射支架
  • 注射用糊劑和凝膠
  • 注射用微粒製劑

第7章 全球注射用生物材料市場：依生物材料功能分類

  • 組織再生
  • 藥物輸送
  • 細胞遞送
  • 生長因子的輸送
  • 基因和核酸的遞送
  • 免疫調節

第8章 全球注射用生物材料市場：依交聯機制分類

  • 物理交聯
  • 化學交聯
  • 離子交聯
  • 酵素交聯
  • 光交聯
  • 熱致交聯
  • 點選化學交聯
  • 動態共用交聯

第9章 全球注射用生物材料市場：依給藥途徑分類

  • 關節內注射
  • 肌肉內注射
  • 皮下注射
  • 皮內注射
  • 靜脈注射
  • 病灶內注射
  • 其他給藥途徑

第10章 全球注射用生物材料市場：依分解曲線分類

  • 快速分解的生物材料
  • 具有中等生物分解性的生物材料
  • 緩慢分解的生質能材料
  • 不可分解生物材料

第11章 全球注射用生物材料市場：依治療應用分類

  • 在整形外科和肌肉骨骼系統的應用
  • 創傷治療與軟組織修復
  • 心血管應用
  • 神經學用途
  • 眼科應用
  • 牙科用途
  • 泌尿系統用途
  • 婦科應用
  • 其他治療用途

第12章 全球注射用生物材料市場：依最終用戶分類

  • 醫院和診所
  • 專業外科中心
  • 學術和研究機構
  • 製藥和生物技術公司
  • 醫療設備製造商
  • 受託研究機構
  • 再生醫學中心

第13章 全球注射用生物材料市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第14章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第15章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第16章：公司簡介

  • CollPlant Biotechnologies Ltd.
  • Anika Therapeutics, Inc.
  • Biogelx Ltd.
  • Regentis Biomaterials Ltd.
  • Geistlich Pharma AG
  • Matricel GmbH
  • Typeone Srl
  • Xihong Biopharma
  • AURIN Co., Ltd.
  • T&R Biofab Co., Ltd.
  • ReGelTec, Inc.
  • Gel4Med, Inc.
  • Advanced BioMatrix
  • Humabiologics, Inc.
  • Collagen Solutions plc
  • Rousselot
  • Merz Aesthetics
  • Matritech
Product Code: SMRC39156

According to Stratistics MRC, the Global Injectable Biomaterials Market is accounted for $13.3 billion in 2026 and is expected to reach $27.8 billion by 2034 growing at a CAGR of 9.7% during the forecast period. The Injectable Biomaterials Market focuses on injectable biomaterial formulations used for tissue regeneration, therapeutic delivery, wound repair, and minimally invasive medical interventions. Key materials include injectable hydrogels, collagen and extracellular-matrix products, synthetic polymers, composites, and scaffold-based systems capable of conforming to damaged tissue sites. Market growth is supported by rising demand for minimally invasive procedures, increasing orthopedic and tissue-related conditions, progress in regenerative medicine, and broader use of biomaterials in drug and cell delivery. Advances in biodegradable, biocompatible, and stimuli-responsive materials are enhancing treatment effectiveness. North America, Europe, and Asia-Pacific remain significant regions due to advanced healthcare systems, research investments, technological development, and increasing clinical applications.

Market Dynamics:

Driver:

Increasing Prevalence of Orthopedic and Musculoskeletal Disorders

The expanding global burden of orthopedic and musculoskeletal conditions is contributing significantly to demand for injectable biomaterial technologies. Disorders including osteoarthritis, cartilage deterioration, bone injuries, tendon damage, and disc degeneration increasingly require effective tissue-repair approaches. Injectable biomaterials offer the potential to reach damaged areas through minimally invasive administration while providing mechanical support, localized therapeutic delivery, or an environment conducive to regeneration. Demographic aging, increasing obesity, participation in physical activities, sports injuries, and longer lifespans are collectively increasing the number of patients requiring musculoskeletal care. These trends are encouraging continued development and clinical investigation of injectable hydrogels, collagen matrices, bone substitutes, and regenerative biomaterial formulations.

Restraint:

High Development and Manufacturing Costs

The substantial financial burden associated with developing and producing injectable biomaterials can constrain market expansion. Companies must invest heavily in material research, formulation optimization, biocompatibility testing, preclinical evaluations, clinical investigations, and regulatory compliance before introducing products commercially. Production also requires specialized facilities, sterile manufacturing environments, sophisticated processing technologies, and rigorous quality-control systems, increasing overall costs. These requirements can create significant barriers for startups and smaller biotechnology firms that have limited access to capital. High investment needs may therefore extend development timelines, reduce the number of commercially viable projects, and make competition more difficult for emerging companies compared with larger organizations possessing established infrastructure and stronger financial capabilities.

Opportunity:

Development of Smart and Stimuli-Responsive Biomaterials

Smart and stimuli-responsive injectable biomaterials offer an emerging avenue for market expansion by enabling materials to react to specific biological or environmental conditions. These systems may respond to temperature, acidity, enzymes, light, or other physiological signals, allowing controlled changes in structure or release of therapeutic substances. Such functionality can help deliver drugs and growth factors more precisely while potentially limiting exposure to healthy surrounding tissues. Research into thermally responsive, enzyme-sensitive, self-healing, and photocrosslinkable injectable formulations is increasing the range of possible applications. As these advanced technologies progress toward clinical use, they could differentiate new products, improve therapeutic precision, and open additional opportunities in regenerative medicine and localized drug delivery.

Threat:

Supply Chain Disruptions and Raw Material Availability

Dependence on specialized raw materials makes injectable biomaterial manufacturers vulnerable to supply chain disruptions. Production may require high-quality collagen, gelatin, hyaluronic acid, polymers, peptides, proteins, crosslinking chemicals, and other carefully controlled ingredients. Supply shortages, transportation problems, geopolitical events, supplier concentration, and raw material price fluctuations can increase manufacturing costs or interrupt production. Biological ingredients can present additional challenges because they require traceable sourcing, stringent quality standards, and reliable suppliers, making rapid substitution difficult. Prolonged disruptions could delay product availability, increase prices, and affect healthcare supply continuity. Manufacturers may consequently need multiple qualified suppliers, stronger inventory planning, and more resilient procurement strategies to manage these potential threats.

Covid-19 Impact:

The COVID-19 outbreak created substantial short-term challenges for the Injectable Biomaterials Market, primarily through postponements of elective treatments, interruptions in regenerative medicine research, delays in clinical investigations, and disruptions across medical supply chains. Healthcare facilities redirected resources toward pandemic management, limiting procedures involving orthopedic repair, tissue regeneration, and other injectable biomaterial applications. Research and development activities were additionally affected by laboratory restrictions and reduced clinical access. At the same time, the pandemic stimulated research into biomaterials for regenerative medicine, tissue damage, and immune-related applications. Following the restoration of routine healthcare services, deferred procedures and renewed research activities helped establish conditions for market recovery.

The Natural Biomaterials segment is expected to be the largest during the forecast period

The Natural Biomaterials segment is expected to account for the largest market share during the forecast period, supported by favorable biological characteristics and extensive applicability in injectable therapies. Collagen, hyaluronic acid, gelatin, alginate, chitosan, fibrin, and silk are valued for their compatibility with biological environments and their ability to facilitate cellular interactions and tissue regeneration. These materials can be incorporated into injectable hydrogels and other formulations for tissue repair, therapeutic delivery, and regenerative medicine. Their capacity to mimic aspects of natural extracellular environments makes them particularly attractive for healthcare applications. Continued research and formulation improvements are further strengthening their role in advanced injectable biomaterial development.

The Neurological Applications segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Neurological Applications segment is predicted to witness the highest growth rate, driven by growing interest in injectable biomaterials for nervous-system regeneration and repair. Injectable hydrogels are particularly promising because they can be introduced through minimally invasive procedures while creating supportive environments resembling native neural tissue. These systems can facilitate localized delivery of therapeutic agents, cells, and growth factors to difficult-to-reach areas such as the brain, spinal cord, and peripheral nerves. Their biodegradability, flexibility, and capacity for in-situ gelation further strengthen their potential. Continued research into neural tissue engineering and advanced injectable hydrogel platforms is expected to expand their use in neurological regenerative therapies.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by sophisticated healthcare systems, extensive biomedical research, and increasing use of regenerative therapies. Strong investments in biomaterial development, tissue engineering, biotechnology, and minimally invasive healthcare are creating favorable market conditions. The region also has a well-developed ecosystem of technology companies, academic institutions, clinical centers, and research organizations supporting innovation in injectable materials. Growing applications in orthopedic repair, wound management, tissue regeneration, and therapeutic delivery are contributing to regional demand. Furthermore, continued clinical research, technological advancement, and commercialization efforts are expected to strengthen North America's position in the injectable biomaterials industry.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by improving medical infrastructure, greater investment in regenerative healthcare, and rising acceptance of minimally invasive treatment approaches. Expanding healthcare needs across the region are increasing opportunities for orthopedic, tissue-repair, and regenerative applications. Countries including China, Japan, South Korea, and India are strengthening biomaterials research and biotechnology capabilities, supporting technological advancement. Rising healthcare spending and broader availability of sophisticated medical treatments are further encouraging market development. Strong growth across the regional biomaterials and regenerative medicine sectors provides a favorable foundation for expanding injectable biomaterial applications and accelerating adoption throughout Asia-Pacific.

Key players in the market

Some of the key players in Injectable Biomaterials Market include CollPlant Biotechnologies Ltd., Anika Therapeutics, Inc., Biogelx Ltd., Regentis Biomaterials Ltd., Geistlich Pharma AG, Matricel GmbH, Typeone S.r.l., Xihong Biopharma, AURIN Co., Ltd., T&R Biofab Co., Ltd., ReGelTec, Inc., Gel4Med, Inc., Advanced BioMatrix, Humabiologics, Inc., Collagen Solutions plc, Rousselot, Merz Aesthetics, Matritech.

Key Developments:

In May 2026, AURIN's official website reports that it signed a co-development agreement for PDRN-based cosmeceutical ingredients. The collaboration is focused on developing PDRN-based ingredients, fitting AURIN's regenerative-biomaterials platform centered on collagen, gelatin, and PDRN.

In April 2026, Regentis Biomaterials announced a collaboration with Humanitas Research Hospital in Milan, Italy, together with cartilage-repair expert Prof. Elizaveta Kon, to support the European clinical adoption and commercial deployment strategy for its GelrinC regenerative hydrogel.

In February 2026, T&R Biofab entered into an MOU with Asrigen for the joint research, development, and commercialization of advanced orthopedic regenerative medical devices.

Material Types Covered:

  • Natural Biomaterials
  • Synthetic Biomaterials
  • Semi-Synthetic Biomaterials
  • Composite Biomaterials

Formulation Types Covered:

  • Injectable Hydrogels
  • Injectable Scaffolds
  • Injectable Pastes and Gels
  • Injectable Particulate Systems

Biomaterial Functions Covered:

  • Tissue Regeneration
  • Drug Delivery
  • Cell Delivery
  • Growth Factor Delivery
  • Gene and Nucleic Acid Delivery
  • Immunomodulation

Crosslinking Mechanisms Covered:

  • Physical Crosslinking
  • Chemical Crosslinking
  • Ionic Crosslinking
  • Enzymatic Crosslinking
  • Photocrosslinking
  • Thermally Induced Crosslinking
  • Click-Chemistry Crosslinking
  • Dynamic Covalent Crosslinking

Administration Routes Covered:

  • Intra-articular Injection
  • Intramuscular Injection
  • Subcutaneous Injection
  • Intradermal Injection
  • Intravenous Injection
  • Intralesional Injection
  • Other Administration Routes

Degradation Profiles Covered:

  • Rapidly Degradable Biomaterials
  • Moderately Degradable Biomaterials
  • Slowly Degradable Biomaterials
  • Non-Degradable Biomaterials

Therapeutic Applications Covered:

  • Orthopedic and Musculoskeletal Applications
  • Wound Healing and Soft Tissue Repair
  • Cardiovascular Applications
  • Neurological Applications
  • Ophthalmic Applications
  • Dental Applications
  • Urological Applications
  • Gynecological Applications
  • Other Therapeutic Applications

End Users Covered:

  • Hospitals and Clinics
  • Specialty Surgical Centers
  • Academic and Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Medical Device Companies
  • Contract Research Organizations
  • Regenerative Medicine Centers

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Injectable Biomaterials Market, By Material Type

  • 5.1 Natural Biomaterials
  • 5.2 Synthetic Biomaterials
  • 5.3 Semi-Synthetic Biomaterials
  • 5.4 Composite Biomaterials

6 Global Injectable Biomaterials Market, By Formulation Type

  • 6.1 Injectable Hydrogels
  • 6.2 Injectable Scaffolds
  • 6.3 Injectable Pastes and Gels
  • 6.4 Injectable Particulate Systems

7 Global Injectable Biomaterials Market, By Biomaterial Function

  • 7.1 Tissue Regeneration
  • 7.2 Drug Delivery
  • 7.3 Cell Delivery
  • 7.4 Growth Factor Delivery
  • 7.5 Gene and Nucleic Acid Delivery
  • 7.6 Immunomodulation

8 Global Injectable Biomaterials Market, By Crosslinking Mechanism

  • 8.1 Physical Crosslinking
  • 8.2 Chemical Crosslinking
  • 8.3 Ionic Crosslinking
  • 8.4 Enzymatic Crosslinking
  • 8.5 Photocrosslinking
  • 8.6 Thermally Induced Crosslinking
  • 8.7 Click-Chemistry Crosslinking
  • 8.8 Dynamic Covalent Crosslinking

9 Global Injectable Biomaterials Market, By Administration Route

  • 9.1 Intra-articular Injection
  • 9.2 Intramuscular Injection
  • 9.3 Subcutaneous Injection
  • 9.4 Intradermal Injection
  • 9.5 Intravenous Injection
  • 9.6 Intralesional Injection
  • 9.7 Other Administration Routes

10 Global Injectable Biomaterials Market, By Degradation Profile

  • 10.1 Rapidly Degradable Biomaterials
  • 10.2 Moderately Degradable Biomaterials
  • 10.3 Slowly Degradable Biomaterials
  • 10.4 Non-Degradable Biomaterials

11 Global Injectable Biomaterials Market, By Therapeutic Application

  • 11.1 Orthopedic and Musculoskeletal Applications
  • 11.2 Wound Healing and Soft Tissue Repair
  • 11.3 Cardiovascular Applications
  • 11.4 Neurological Applications
  • 11.5 Ophthalmic Applications
  • 11.6 Dental Applications
  • 11.7 Urological Applications
  • 11.8 Gynecological Applications
  • 11.9 Other Therapeutic Applications

12 Global Injectable Biomaterials Market, By End User

  • 12.1 Hospitals and Clinics
  • 12.2 Specialty Surgical Centers
  • 12.3 Academic and Research Institutions
  • 12.4 Pharmaceutical and Biotechnology Companies
  • 12.5 Medical Device Companies
  • 12.6 Contract Research Organizations
  • 12.7 Regenerative Medicine Centers

13 Global Injectable Biomaterials Market, By Geography

  • 13.1 North America
    • 13.1.1 United States
    • 13.1.2 Canada
    • 13.1.3 Mexico
  • 13.2 Europe
    • 13.2.1 United Kingdom
    • 13.2.2 Germany
    • 13.2.3 France
    • 13.2.4 Italy
    • 13.2.5 Spain
    • 13.2.6 Netherlands
    • 13.2.7 Belgium
    • 13.2.8 Sweden
    • 13.2.9 Switzerland
    • 13.2.10 Poland
    • 13.2.11 Rest of Europe
  • 13.3 Asia Pacific
    • 13.3.1 China
    • 13.3.2 Japan
    • 13.3.3 India
    • 13.3.4 South Korea
    • 13.3.5 Australia
    • 13.3.6 Indonesia
    • 13.3.7 Thailand
    • 13.3.8 Malaysia
    • 13.3.9 Singapore
    • 13.3.10 Vietnam
    • 13.3.11 Rest of Asia Pacific
  • 13.4 South America
    • 13.4.1 Brazil
    • 13.4.2 Argentina
    • 13.4.3 Colombia
    • 13.4.4 Chile
    • 13.4.5 Peru
    • 13.4.6 Rest of South America
  • 13.5 Rest of the World (RoW)
    • 13.5.1 Middle East
      • 13.5.1.1 Saudi Arabia
      • 13.5.1.2 United Arab Emirates
      • 13.5.1.3 Qatar
      • 13.5.1.4 Israel
      • 13.5.1.5 Rest of Middle East
    • 13.5.2 Africa
      • 13.5.2.1 South Africa
      • 13.5.2.2 Egypt
      • 13.5.2.3 Morocco
      • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

  • 14.1 Industry Value Network and Supply Chain Assessment
  • 14.2 White-Space and Opportunity Mapping
  • 14.3 Product Evolution and Market Life Cycle Analysis
  • 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

  • 15.1 Mergers and Acquisitions
  • 15.2 Partnerships, Alliances, and Joint Ventures
  • 15.3 New Product Launches and Certifications
  • 15.4 Capacity Expansion and Investments
  • 15.5 Other Strategic Initiatives

16 Company Profiles

  • 16.1 CollPlant Biotechnologies Ltd.
  • 16.2 Anika Therapeutics, Inc.
  • 16.3 Biogelx Ltd.
  • 16.4 Regentis Biomaterials Ltd.
  • 16.5 Geistlich Pharma AG
  • 16.6 Matricel GmbH
  • 16.7 Typeone S.r.l.
  • 16.8 Xihong Biopharma
  • 16.9 AURIN Co., Ltd.
  • 16.10 T&R Biofab Co., Ltd.
  • 16.11 ReGelTec, Inc.
  • 16.12 Gel4Med, Inc.
  • 16.13 Advanced BioMatrix
  • 16.14 Humabiologics, Inc.
  • 16.15 Collagen Solutions plc
  • 16.16 Rousselot
  • 16.17 Merz Aesthetics
  • 16.18 Matritech

List of Tables

  • Table 1 Global Injectable Biomaterials Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Injectable Biomaterials Market Outlook, By Material Type (2023-2034) ($MN)
  • Table 3 Global Injectable Biomaterials Market Outlook, By Natural Biomaterials (2023-2034) ($MN)
  • Table 4 Global Injectable Biomaterials Market Outlook, By Synthetic Biomaterials (2023-2034) ($MN)
  • Table 5 Global Injectable Biomaterials Market Outlook, By Semi-Synthetic Biomaterials (2023-2034) ($MN)
  • Table 6 Global Injectable Biomaterials Market Outlook, By Composite Biomaterials (2023-2034) ($MN)
  • Table 7 Global Injectable Biomaterials Market Outlook, By Formulation Type (2023-2034) ($MN)
  • Table 8 Global Injectable Biomaterials Market Outlook, By Injectable Hydrogels (2023-2034) ($MN)
  • Table 9 Global Injectable Biomaterials Market Outlook, By Injectable Scaffolds (2023-2034) ($MN)
  • Table 10 Global Injectable Biomaterials Market Outlook, By Injectable Pastes and Gels (2023-2034) ($MN)
  • Table 11 Global Injectable Biomaterials Market Outlook, By Injectable Particulate Systems (2023-2034) ($MN)
  • Table 12 Global Injectable Biomaterials Market Outlook, By Biomaterial Function (2023-2034) ($MN)
  • Table 13 Global Injectable Biomaterials Market Outlook, By Tissue Regeneration (2023-2034) ($MN)
  • Table 14 Global Injectable Biomaterials Market Outlook, By Drug Delivery (2023-2034) ($MN)
  • Table 15 Global Injectable Biomaterials Market Outlook, By Cell Delivery (2023-2034) ($MN)
  • Table 16 Global Injectable Biomaterials Market Outlook, By Growth Factor Delivery (2023-2034) ($MN)
  • Table 17 Global Injectable Biomaterials Market Outlook, By Gene and Nucleic Acid Delivery (2023-2034) ($MN)
  • Table 18 Global Injectable Biomaterials Market Outlook, By Immunomodulation (2023-2034) ($MN)
  • Table 19 Global Injectable Biomaterials Market Outlook, By Crosslinking Mechanism (2023-2034) ($MN)
  • Table 20 Global Injectable Biomaterials Market Outlook, By Physical Crosslinking (2023-2034) ($MN)
  • Table 21 Global Injectable Biomaterials Market Outlook, By Chemical Crosslinking (2023-2034) ($MN)
  • Table 22 Global Injectable Biomaterials Market Outlook, By Ionic Crosslinking (2023-2034) ($MN)
  • Table 23 Global Injectable Biomaterials Market Outlook, By Enzymatic Crosslinking (2023-2034) ($MN)
  • Table 24 Global Injectable Biomaterials Market Outlook, By Photocrosslinking (2023-2034) ($MN)
  • Table 25 Global Injectable Biomaterials Market Outlook, By Thermally Induced Crosslinking (2023-2034) ($MN)
  • Table 26 Global Injectable Biomaterials Market Outlook, By Click-Chemistry Crosslinking (2023-2034) ($MN)
  • Table 27 Global Injectable Biomaterials Market Outlook, By Dynamic Covalent Crosslinking (2023-2034) ($MN)
  • Table 28 Global Injectable Biomaterials Market Outlook, By Administration Route (2023-2034) ($MN)
  • Table 29 Global Injectable Biomaterials Market Outlook, By Intra-articular Injection (2023-2034) ($MN)
  • Table 30 Global Injectable Biomaterials Market Outlook, By Intramuscular Injection (2023-2034) ($MN)
  • Table 31 Global Injectable Biomaterials Market Outlook, By Subcutaneous Injection (2023-2034) ($MN)
  • Table 32 Global Injectable Biomaterials Market Outlook, By Intradermal Injection (2023-2034) ($MN)
  • Table 33 Global Injectable Biomaterials Market Outlook, By Intravenous Injection (2023-2034) ($MN)
  • Table 34 Global Injectable Biomaterials Market Outlook, By Intralesional Injection (2023-2034) ($MN)
  • Table 35 Global Injectable Biomaterials Market Outlook, By Other Administration Routes (2023-2034) ($MN)
  • Table 36 Global Injectable Biomaterials Market Outlook, By Degradation Profile (2023-2034) ($MN)
  • Table 37 Global Injectable Biomaterials Market Outlook, By Rapidly Degradable Biomaterials (2023-2034) ($MN)
  • Table 38 Global Injectable Biomaterials Market Outlook, By Moderately Degradable Biomaterials (2023-2034) ($MN)
  • Table 39 Global Injectable Biomaterials Market Outlook, By Slowly Degradable Biomaterials (2023-2034) ($MN)
  • Table 40 Global Injectable Biomaterials Market Outlook, By Non-Degradable Biomaterials (2023-2034) ($MN)
  • Table 41 Global Injectable Biomaterials Market Outlook, By Therapeutic Application (2023-2034) ($MN)
  • Table 42 Global Injectable Biomaterials Market Outlook, By Orthopedic and Musculoskeletal Applications (2023-2034) ($MN)
  • Table 43 Global Injectable Biomaterials Market Outlook, By Wound Healing and Soft Tissue Repair (2023-2034) ($MN)
  • Table 44 Global Injectable Biomaterials Market Outlook, By Cardiovascular Applications (2023-2034) ($MN)
  • Table 45 Global Injectable Biomaterials Market Outlook, By Neurological Applications (2023-2034) ($MN)
  • Table 46 Global Injectable Biomaterials Market Outlook, By Ophthalmic Applications (2023-2034) ($MN)
  • Table 47 Global Injectable Biomaterials Market Outlook, By Dental Applications (2023-2034) ($MN)
  • Table 48 Global Injectable Biomaterials Market Outlook, By Urological Applications (2023-2034) ($MN)
  • Table 49 Global Injectable Biomaterials Market Outlook, By Gynecological Applications (2023-2034) ($MN)
  • Table 50 Global Injectable Biomaterials Market Outlook, By Other Therapeutic Applications (2023-2034) ($MN)
  • Table 51 Global Injectable Biomaterials Market Outlook, By End User (2023-2034) ($MN)
  • Table 52 Global Injectable Biomaterials Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 53 Global Injectable Biomaterials Market Outlook, By Specialty Surgical Centers (2023-2034) ($MN)
  • Table 54 Global Injectable Biomaterials Market Outlook, By Academic and Research Institutions (2023-2034) ($MN)
  • Table 55 Global Injectable Biomaterials Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 56 Global Injectable Biomaterials Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 57 Global Injectable Biomaterials Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 58 Global Injectable Biomaterials Market Outlook, By Regenerative Medicine Centers (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.